10-K: Kairos Pharma Reports 2024 Results, Highlights Clinical Progress and Financial Position

Kairos Pharma's 2024 10-K filing details the company's ongoing clinical trials, financial status, and strategic focus on developing cancer therapeutics.

Summary

• Kairos Pharma, a clinical-stage biopharmaceutical company, is focused on developing therapeutics for cancer patients.
• The company's mission is to advance innovative therapeutics targeting therapeutic resistance and immune suppression.
• Kairos Pharma's portfolio includes antibodies and small molecules for treating prostate, lung, and breast cancer, as well as glioblastoma.
• The company has licensed proprietary technologies from Cedars-Sinai Medical Center.
• As of the date of the Annual Report, none of Kairos Pharma's product candidates have been approved by the FDA or any comparable foreign regulator.
• The company initiated three clinical trials in the fall of 2023 for KROS 201 and ENV 105.
• A Phase 2 trial of ENV 105 in prostate cancer showed a 62% clinical benefit rate.
• The NIH awarded a $3.2 million grant to Cedars-Sinai to support the development of ENV105's mechanism of action and companion biomarkers.
• Global cancer drug spending was valued at approximately $232 billion in 2024, and is expected to reach some $532 billion by 2031.
• The company's strategy involves advancing its product portfolio through clinical development and leveraging academic and industry collaborations.
• Kairos Pharma closed its IPO on September 17, 2024, raising $6.2 million in gross proceeds.
• On November 12, 2024, the Company entered into an equity line of credit agreement with Helena Global Investment Opportunities I Ltd.
• On January 14, 2025, the Company entered into a securities purchase agreement for the sale and issuance of 2,500,000 units for gross proceeds of $3,497,500.
• The company identified material weaknesses in its internal control over financial reporting.
• As of December 31, 2024, the company had one full-time and three part-time employees.
• The company expects its cash to last at least 12 months from the date of filing this Annual Report.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has made progress in its clinical trials and secured funding, it is still in the early stages of development and faces significant risks and challenges.

Positives

• ENV 105 demonstrated a 62% clinical benefit rate in a Phase 2 prostate cancer trial.
• The NIH awarded a $3.2 million grant to support ENV 105 development.
• The company successfully completed its IPO, raising $6.2 million.
• The company secured an equity line of credit agreement for up to $30 million.
• The company closed a PIPE offering for gross proceeds of $3,497,500.
• The company expects its cash to last at least 12 months from the date of filing this Annual Report.

Negatives

• None of Kairos Pharma's product candidates have been approved by the FDA or any comparable foreign regulator.
• The company has incurred significant operating losses since its inception.
• The company identified material weaknesses in its internal control over financial reporting.

Risks

• The company is dependent on the success of its initial drug candidates, which are still under clinical development.
• The company requires substantial additional funding to meet its financial needs.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, and involve an uncertain outcome.
• Serious adverse events or undesirable side effects of the company's product candidates may be identified during development or after approval.
• The company faces substantial competition from large, well-funded, and experienced competitors.
• The company may not be able to maintain a listing of its common stock on NYSE American.
• The trading price of the company's common stock may be volatile, and investors could lose all or part of their investment.

Future Outlook

Kairos Pharma expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances its product candidates through clinical development, seeks regulatory approval, and operates as a public company.

Industry Context

The global cancer drug market is projected to reach $532 billion by 2031, driven by targeted therapies and immuno-oncology. Kairos Pharma is positioned to advance immunotherapies targeting drug resistance and immune suppression.

Comparison to Industry Standards

• The global immune checkpoint inhibitor market size was $47.4 billion in 2023 and anticipated to be $189.1 billion in 2032 with a CAGR of 16,7% from 2024 to 2032.
• The global small-molecule cancer therapies market size was valued at $175.3 billion in 2021 and is expected to have a CAGR of 5.44% from 2022 to 2030.
• The global peptide therapeutics market size was $117.3 billion in 2024 and is estimated to grow CAGR of 10.77% from 2025 to 2030.

Related Party Transactions

• Shareholders of the Company, and a company whose principal stockholder is also a stockholder of the Company, advanced the Company $14.
• The Company entered into note payable agreements with three of its officers in the aggregate total of $142.
• The Company entered into agreements with CEO.CA Technologies Ltd. and Belair Capital Advisors Inc., shareholders of the Company, pursuant to which they will provide certain services to the Company.

Stakeholder Impact

• The company's success depends on its ability to attract, retain, and motivate exceptional employees.
• The company is committed to efforts to increase diversity and foster an inclusive work environment that supports its workforce.
• The company's goal is to unlock the power of the immune system to improve the quality of life of cancer patients and transform their outcomes.

Next Steps

• Complete enrollment of prostate patients in a randomized multi-institutional Phase 2 trial of ENV 105.
• Complete enrollment in a Phase 1 trial of ENV105 for patients with non-small lung cancer on Tagrisso.
• Initiate a Phase 1 trial of activated T cell therapy for KROS 201 in patients with glioblastoma.
• Complete pre-IND studies for the checkpoint inhibitor KROS 101.
• Continue to advance our pipeline of immunotherapeutics for clinical trials.

Key Dates

Keywords

Kairos Pharma, ENV 105, KROS 201, clinical trials, cancer therapeutics, biopharmaceutical, IPO, financial results, regulatory approval, intellectual property